Holen Sie sich die Stockscreener-App
55.11
3.52%
-2.01
Handel nachbörslich:
53.50
-1.61
-2.92%
Schlusskurs vom Vortag:
$57.12
Offen:
$54.93
24-Stunden-Volumen:
247.23K
Relative Volume:
3.93
Marktkapitalisierung:
$4.19B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-0.74%
1M Leistung:
+134.91%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$52.00
$56.60
1-Wochen-Bereich:
$47.74
$61.00
52-Wochen-Spanne:
$9.95
$61.00
Jyong Biotech Ltd Stock (MENS) Company Profile
Firmenname
Jyong Biotech Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie MENS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
55.11 | 4.55B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Jyong Biotech Ltd Aktie (MENS) Neueste Nachrichten
Jyong Biotech (NASDAQ:MENS) Shares Gap UpHere's Why - MarketBeat
These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025 - The Motley Fool
Experts discuss the transformative potential of AI for BPH - Urology Times
Jennifer Robles, MD, on future advancements in HoLEP - Urology Times
Jyong Biotech to present clinical data from studies of BOTRESO, MCS-8 - MSN
Jyong Biotech (NASDAQ:MENS) Stock Price Down 6.7%What's Next? - MarketBeat
Jyong Biotech shares rise 1.83% after-hours after participating in the 22nd Urological Association of Asia Congress. - AInvest
Jyong Biotech shares fall 1.93% after-hours following participation in the 22nd Urological Association of Asia Congress. - AInvest
Jyong Biotech Ltd. Participated in the 22nd Urological - GlobeNewswire
Breakthrough: Taiwan's First FDA Phase 3 Botanical Drug BOTRESO Shows Promise in $9.8B BPH Market - Stock Titan
Jyong Biotech (NASDAQ:MENS) Shares Up 10.5%Here's What Happened - MarketBeat
Biopharma IPO drought continues: chance of rain expected? - BioWorld MedTech
Jyong Biotech (NASDAQ:MENS) Shares Gap DownTime to Sell? - MarketBeat
Jyong Biotech (NASDAQ:MENS) Hits New 12-Month HighStill a Buy? - MarketBeat
Jyong Biotech (NASDAQ:MENS) Stock Price Down 12.3%What's Next? - MarketBeat
Jyong Biotech's Plant‑Based Pipeline Targets Huge Markets But Risks Remain - Seeking Alpha
Jyong Biotech Ltd.'s Quiet Period Will End on July 28th (NASDAQ:MENS) - MarketBeat
Jyong Biotech Ltd. shares rise 6.64% intraday as SK Hynix reports Q2 2025 earnings. - AInvest
Jyong Biotech Ltd. Completes Nasdaq IPO and Showcases MCS®-2 at BIO 2025 International Convention - Nasdaq
Jyong Biotech Completes Nasdaq IPO, Participates in BIO 2025 Convention. - AInvest
Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention - GlobeNewswire
Taiwan's Jyong Biotech Takes On $9.8B BPH Market With Revolutionary Plant-Based Treatment After Nasdaq IPO - Stock Titan
Jyong Biotech Ltd.’s Quiet Period Set To Expire on July 28th (NASDAQ:MENS) - Defense World
Biopharma financings total $28.7B in H1, down 59% from 2024 - BioWorld MedTech
Jyong Biotech shares rise 3.85% in premarket after rating upgrade and CEO's Nasdaq bell ringing. - AInvest
Yong Biotech Ltd (Nasdaq:MENS) Marks Milestone at Nasdaq Composite MarketSite - Kalkine Media
Jyong Biotech shares fall 3.12% in after-hours after Wall Street Zen upgrades rating to 'hold' and CEO rings closing bell at Nasdaq. - AInvest
Pre-market Movers: BGLC, ATAI, GOVX, SNGX... - RTTNews
Jyong Biotech shares fall 4.92% in after-hours following a 34.80% surge post-Nasdaq listing and 11.04% gain over the past five days. - AInvest
Jyong Biotech shares rise 2.11% intraday as biotech sector gains and company completes $20M IPO. - AInvest
Jyong Biotech shares rise 11.82% intraday after successful $20 million IPO and addition to Nasdaq Composite Index. - AInvest
Jyong’s $20M US IPO to help refile NDA of urological botanic drug - BioWorld MedTech
Jyong Biotech Soars 11.13% Post $20M IPO - AInvest
MENSJyong Biotech Ltd. Latest Stock News & Market Updates - Stock Titan
Jyong Biotech Plunges 10.98% Despite IPO Surge - AInvest
Taiwan’s Jyong Biotech doubles in value on Nasdaq debut - Investing.com
Taiwan's Jyong Biotech Makes Nasdaq Debut: $20M IPO Targets Breakthrough in Urinary Disease Treatment - Stock Titan
Amy Krambeck, MD, on innovation and building strong programs in endourology - Urology Times
Amy E. Krambeck, MD, on patient selection for HoLEP - Urology Times
Jyong Biotech Seeks US IPO On Thin Capitalization And Uphill Regulatory Battle (MENS) - Seeking Alpha
MENS IPO NewsUrinary disease biotech Jyong Biotech sets terms for $19 million US IPO - renaissancecapital.com
Expert on Aquablation’s comparable long-term outcomes in prostates of different sizes - Urology Times
Ravi Munver, MD, discusses the versatility of Aquablation treatment for BPH - Urology Times
Dr. Das on his experience with HoLEP for treating BPH - Urology Times
Commercial-ready Taiwanese biotech developing therapies for urinary diseases. - renaissancecapital.com
Study assesses Rezum therapy in large prostates - Urology Times
JYB IPO NewsUrinary disease biotech Jyong Biotech withdraws $40 million US IPO - renaissancecapital.com
Dr. Elterman on the new wave of BPH stents - Urology Times
Dr. Elterman on the future of stents for benign prostatic hyperplasia - Urology Times
Jyong Biotech Ltd. Begins U.S. IPO Rollout (Pending:JYB) - Seeking Alpha
Dr. Munver highlights positive impact of Aquablation for BPH - Urology Times
Finanzdaten der Jyong Biotech Ltd-Aktie (MENS)
Es liegen keine Finanzdaten für Jyong Biotech Ltd (MENS) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):